share_log

Exicure | 8-K: Exicure, Inc. Reports Second Quarter 2024 Financial Results

Exicure | 8-K: Exicure, Inc. Reports Second Quarter 2024 Financial Results

Exicure | 8-K：Exicure, Inc. 公布2024年第二季度财务业绩
美股SEC公告 ·  08/13 16:24

Moomoo AI 已提取核心信息

On August 13, 2024, Exicure, Inc., a biotechnology company based in Chicago, reported its financial results for the second quarter ended June 30, 2024. The company, which has been focusing on nucleic acid therapies, announced a significant reduction in force and suspension of preclinical activities in September 2022, and is currently exploring strategic alternatives to maximize shareholder value. Exicure's cash and cash equivalents stood at $0.5 million, down from $0.8 million at the end of 2023, indicating a need for immediate additional funding to continue operations. General and administrative expenses decreased to $1.2 million for the quarter, down from $5.6 million in the same period last year, primarily due to reduced payroll and operating costs. The company also reported other income of $0.6 million from the sale of clinical product samples. Despite cost reductions, Exicure incurred a net loss of $0.6 million for the quarter, an improvement from a net loss of $5.8 million in the previous year. The company's management has expressed concern about the sufficiency of its cash reserves to fund ongoing operations and the urgent need for additional financing.
On August 13, 2024, Exicure, Inc., a biotechnology company based in Chicago, reported its financial results for the second quarter ended June 30, 2024. The company, which has been focusing on nucleic acid therapies, announced a significant reduction in force and suspension of preclinical activities in September 2022, and is currently exploring strategic alternatives to maximize shareholder value. Exicure's cash and cash equivalents stood at $0.5 million, down from $0.8 million at the end of 2023, indicating a need for immediate additional funding to continue operations. General and administrative expenses decreased to $1.2 million for the quarter, down from $5.6 million in the same period last year, primarily due to reduced payroll and operating costs. The company also reported other income of $0.6 million from the sale of clinical product samples. Despite cost reductions, Exicure incurred a net loss of $0.6 million for the quarter, an improvement from a net loss of $5.8 million in the previous year. The company's management has expressed concern about the sufficiency of its cash reserves to fund ongoing operations and the urgent need for additional financing.
2024年8月13日，总部位于芝加哥的生物技术公司exicure报告了截至2024年6月30日的第二季度财务业绩。该公司一直专注于核酸治疗，于2022年9月宣布大规模裁员和暂停临床前活动，目前正在探索战略方案以最大化股东价值。exicure的现金及现金等价物为50万美元，较2023年底的80万美元下降，表明需要立即获得额外资金继续运营。本季度的管理和行政费用为120万美元，较去年同期的560万美元下降，主要是由于减少了工资和运营成本。该公司还从临床产品样本的销售中获得了60万美元的其他收入。尽管削减成本，exicure本季度仍有净亏损60万美元，但较上一年的净亏损580万美元有所改善。公司管理层对资金储备是否足够支持持续运营以及迫切需要额外融资表示担忧。
2024年8月13日，总部位于芝加哥的生物技术公司exicure报告了截至2024年6月30日的第二季度财务业绩。该公司一直专注于核酸治疗，于2022年9月宣布大规模裁员和暂停临床前活动，目前正在探索战略方案以最大化股东价值。exicure的现金及现金等价物为50万美元，较2023年底的80万美元下降，表明需要立即获得额外资金继续运营。本季度的管理和行政费用为120万美元，较去年同期的560万美元下降，主要是由于减少了工资和运营成本。该公司还从临床产品样本的销售中获得了60万美元的其他收入。尽管削减成本，exicure本季度仍有净亏损60万美元，但较上一年的净亏损580万美元有所改善。公司管理层对资金储备是否足够支持持续运营以及迫切需要额外融资表示担忧。
有用
没用

该公告为独立文件：

独立文件1

独立文件2

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间